Skip to content
MARKETS / NASDAQ / RGNX
NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP

Regenxbio Inc. RGNX

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$170.4M
▲ 104.5% YoY
$-193.9M
$-126.4M
In brief

What this company does

REGENXBIO Inc. is a clinical-stage biotechnology company that develops investigational gene therapies using adeno-associated virus (AAV) vectors from its proprietary NAV Technology Platform. As of February 27, 2026, the company employed 371 full-time employees, of which 296 were engaged in research and development activities and 75 were engaged in general administrative activities. Its Good Manufacturing Practices (cGMP) production facility, the REGENXBIO Manufacturing Innovation Center (RMIC), is located at its corporate headquarters in Rockville, Maryland. It is developing surabgene lomparvovec (sura-vec, ABBV-RGX-314) in collaboration with AbbVie to treat patient populations affected by wet age-related macular degeneration and diabetic retinopathy. It is also developing RGX-121 (clemidsogene lanparvovec) and RGX-111 with Nippon Shinyaku to treat Mucopolysaccharidosis type II and Mucopolysaccharidosis type I, both progressive neurodegenerative lysosomal storage disorders.

Written from the business description in REGENXBIO Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth
USD 170.4M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 170.4 · Net income -193.9
200M400M-100M-200M2013201520172019202120232025
Compound annual growth
+14.8%
+2.0%
+36.5%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +2.0% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−114 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -94.6% · Net -113.8%
-500%-1000%2013201520172019202120232025
ROE
FY2025 · ROE -107.0%
10%20%-50%-100%2013201520172019202120232025

Each USD of equity lost 107 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -126.4
50M100M-80M-160M2013201520172019202120232025

Total assetsUSD 453.0M
EquityUSD 102.7M
CashUSD 34.5M
Current ratio2.38×

Equity funds 23% of total assets.

The 13-year record
13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.20.10.10.10.50.20.00.20.00.00.00.00.0
Operating income $B−0.2−0.2−0.3−0.30.2−0.1−0.10.1−0.1−0.1−0.0−0.0−0.0
EBITDA $B·············
Income tax $B0.00.0−0.0−0.00.00.0−0.00.00.0−0.00.00.00.0
Net income $B−0.2−0.2−0.3−0.30.1−0.1−0.10.1−0.1−0.1−0.0−0.0−0.0
Free cash flow $B−0.1−0.2−0.2−0.20.1−0.1−0.10.1−0.1−0.1−0.0··
EPS, diluted $−3.76−4.59−6.02−6.502.91−2.98−2.582.73−2.45−2.38−2.59−1.82−2.50
Dividend / sh $·············
Payout %·············
ROE %−107.0−79.5−63.7−43.822.4−26.9−19.828.9−42.4−33.3−23.0··
Shares out B0.050.050.040.040.040.040.040.040.030.030.030.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 50 reconciliationsAUDITED

Reconciled in 13 of 19 fiscal years. 33 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityBiological Products, (No Diagnostic Substances)
Listed onNASDAQ
Incorporated innot stated in the filings
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image